欢迎访问《中国临床药理学与治疗学》杂志官方网站,今天是

中国临床药理学与治疗学 ›› 2025, Vol. 30 ›› Issue (1): 91-99.doi: 10.12092/j.issn.1009-2501.2025.01.011

• 综述与讲座 • 上一篇    下一篇

抗血小板药物临床应用现状及研发新进展

潘冠星1,5,黄品芳2,5,柴大军3,5,张菁4,5   

  1. 1福建医科大学附属第一医院临床药理研究中心,福州  350005,福建;2福建医科大学附属第一医院药学部,福州  350005,福建;3福建医科大学附属第一医院心血管内科,福州  350005,福建;4复旦大学附属华山医院临床药理研究中心,上海  200040;5福建医科大学附属第一医院滨海院区国家区域医疗中心临床药理研究中心,福州  350212,福建

  • 收稿日期:2024-03-15 修回日期:2024-04-17 出版日期:2025-01-26 发布日期:2025-01-02
  • 通讯作者: 张菁,女,博士,主任药师,博士生导师,研究方向:临床药理学和定量药理学。 E-mail: zhangj_fudan@aliyun.com
  • 作者简介:潘冠星,男,博士,副研究员,研究方向:血小板激活机制与抗血小板药物。 E-mail: PanGX163@163.com
  • 基金资助:
    福建省科技创新联合资金项目(2023Y9044)

Current clinical application and research progress of antiplatelet drugs

PAN Guanxing1,5, HUANG Pinfang2,5, CHAI Dajun3,5, ZHANG Jing4,5   

  1. 1 Clinical Pharmacology Research Center, the First Affiliated Hospital, Fujian Medical University, Fuzhou 350005, Fujian, China; 2 Department of Pharmacy, the First Affiliated Hospital, Fujian Medical University, Fuzhou 350005, Fujian, China; 3 Department of Cardiology, the First Affiliated Hospital, Fujian Medical University, Fuzhou 350005, Fujian, China; 4 Clinical Pharmacology Research Center, Huashan Hospital, Fudan University, Shanghai 200040, China; 5 Clinical Pharmacology Research Center, National Regional Medical Center, Binhai Campus of the First Affiliated Hospital, Fujian Medical University, Fuzhou 350212, Fujian, China
  • Received:2024-03-15 Revised:2024-04-17 Online:2025-01-26 Published:2025-01-02

摘要:

动脉血栓是包括冠心病和中风在内的多种心血管疾病的主要致死病因之一,由于血小板是动脉血栓的主要参与者,抗血小板治疗是心血管疾病患者临床治疗的重要一环。目前,P2Y12受体拮抗剂联合阿司匹林的双联抗血小板疗法为患者提供了长期有效的抗血栓疗效,以替罗非班为代表的αΙIbβ3受体拮抗剂也为突发手术的抗血小板提供了选择,但抗血小板治疗带来的出血风险一直是临床上难以忽视的问题。本文对近年主要的抗血小板药物靶点及进入临床试验的药物进行综述,旨在为抗血小板药物的后续研发提供参考。

关键词: 抗血小板药物, 血小板受体, 药物研发, 临床试验

Abstract:

Arterial thrombosis is a major cause of death in several cardiovascular diseases (CVDs), including coronary heart disease and stroke. Since platelets play a pivotal role in arterial thrombosis, antiplatelet drug is an important part of the clinical therapy of CVD patients. Currently, the long-term antithrombotic effect of the dual antiplatelet therapy of P2Y12 antagonists combined with aspirin are showed to be effective. And αΙIbβ3 antagonists represented by tirofiban are widely used for antiplatelet therapy in emergency surgery. However, the bleeding risk caused by antiplatelet therapy is a clinical issue that cannot be ignored. In order to provide a reference for further research on antiplatelet drugs, this article reviews the major targets of antiplatelet drugs and the drugs that have been under clinical research in recent years.

Key words: antiplatelet drug, platelet receptor, drug development, clinical trial

中图分类号: